Voretigene shows durable 9‑year outcomes

Stephen R. Russell’s latest long-term update on voretigene neparvovec-rzyl adds something gene therapy in inherited retinal disease has often lacked: time. At the American Society of Retina Specialists annual meeting in July 2024, Russell presented eight- and nine-year follow-up from the phase 3 program for the treatment, marketed as Luxturna, in patients with biallelic RPE65-mediated inherited retinal disease. (ophthalmologytimes.com) Ophthalmology Times reported the presentation in August 2024, and the University of Iowa later described the same update as evidence that treated patients continued to show durable effects years after dosing. (eye.medicine.uiowa.edu) That matters because Luxturna was approved as a one-time gene therapy, but the central clinical question has always been how long functional gains last after surgery. (fda.gov) The official U.S. label says the therapy is indicated for patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy who have viable retinal cells. Russell was one of the principal investigators in the phase 3 trial. ### What exactly lasted for nine years? The nine-year update described continued functional benefit after treatment rather than a new short-term efficacy signal. Ophthalmology Times said Russell discussed nine-year data for voretigene neparvovec-rzyl in inherited retinal disease, while the University of Iowa said he shared eight- and nine-year follow-up results from the phase 3 trial. (ophthalmologytimes.com) Ophthalmology360, citing Russell’s ASRS presentation, reported that measures including functional vision, full-field stimulus testing and best-corrected visual acuity showed continued benefit over the study period, with no new treatment-related serious adverse events reported in that summary. That report should be read as a meeting-based account rather than a peer-reviewed full paper, but it helps clarify what investigators mean by durability here: retained function, not cure. (fda.gov) ### Which patients does this apply to? Luxturna is not a general treatment for all inherited retinal disorders. The FDA-approved indication is limited to patients with inherited retinal disease caused by mutations in both copies of the RPE65 gene, and the diagnosis must be confirmed through genetic testing. (ophthalmologytimes.com) The product website also says patients must have viable retinal cells to be considered for treatment. That makes the counseling pathway fairly specific. A patient first needs a molecular diagnosis, then a retinal specialist has to determine whether the phenotype and remaining retinal structure fit the labeled use. The long follow-up data are most relevant once that eligibility question is already on the table. ### Why do nine-year data matter more than the original trial endpoints? (ophthalmology360.com) The original promise of retinal gene therapy was a one-time intervention with lasting effect, but early trials could only prove that over a few years. Long-term follow-up now lets physicians discuss persistence with more precision. The University of Iowa said Russell’s eight- and nine-year update covered the first approved drug therapy for an inherited disease, underscoring how unusual it is to have nearly a decade of follow-up in this category. (fda.gov) Published reviews have already described earlier durability signals at three and four years for voretigene neparvovec. The nine-year update extends that frame materially, even if the newest figures are still being communicated mainly through meeting presentations and secondary reports rather than a fresh full-length journal paper. (fda.gov) ### What should clinicians and families take from this now? Stephen Russell’s presentation supports a more concrete conversation about expectations: some treated patients appear to maintain functional benefit for many years after a single administration. The data do not mean every inherited retinal disease patient is eligible, and they do not remove the need for genetic confirmation, surgical evaluation and long-term follow-up. (eye.medicine.uiowa.edu) The next place to watch is the formal publication trail around the ASRS 2024 update and any future label, registry or conference disclosures from Spark Therapeutics, Roche or academic investigators following treated RPE65 patients over longer intervals. (eye.medicine.uiowa.edu) (ophthalmologytimes.com) (nature.com)